Alkem Medtech公司购买瑞士Occlutech公司55%的心脏器械,价值180.7M欧元,待2026年批准。 Alkem Medtech to buy 55% of Swiss cardiac device firm Occlutech for €180.7M, pending 2026 approvals.

Alkem Medtech公司计划在2026年6月获得监管批准之前,以1.807亿欧元获得瑞士心血管装置制造商Occlutech公司55%的股权,这标志着该公司进入先进的心脏植入器。 Alkem Medtech plans to acquire a 55% stake in Swiss cardiovascular device maker Occlutech for €180.7 million, pending regulatory approvals by June 2026, marking its entry into advanced cardiac implants. 该交易旨在扩大Alkem在美国、欧洲、日本和德国的存在,Occlutech在2025年4 940万欧元的收入中创造了85%。 The deal aims to expand Alkem’s presence in the U.S., Europe, Japan, and Germany, where Occlutech generated 85% of its €49.4 million 2025 revenue. Alkem报告称，2025-2026财年第三季度净利润增长1.6%至1.9%，达到63.6亿卢比，达到65.3亿卢比，收入增长10.7%，达到373.6亿卢比，主要得益于强劲的国际销售。 Alkem reported a 1.6% to 1.9% rise in net profit to ₹636 crore to ₹653 crore for the third quarter of 2025–2026, with revenue up 10.7% to ₹3,736 crore, driven by strong international sales. 收购被视为一项战略举措,旨在增加其生物技术组合,补充其生物技术部门。 The acquisition is seen as a strategic move to grow its medtech portfolio, complementing its biotech arm.